Submit RFI/RFP
Request Consultation
The UK’s Innovative Licensing and Access Pathway (ILAP) aims to help patients get promising and much-needed new medicines more quickly. Announced by the Medicines and Healthcare products Regulatory Agency (MHRA) and several national bodies, this system now helps developers work with all relevant agencies from the earliest stages. ILAP’s process begins with something called the Innovation Passport, which means a medicine can then get coordinated support for clinical trials, data requirements, and market approval, all with the goal of faster access for patients.
In its latest round, three new therapies for serious rare diseases have become the first to join this pathway: a treatment for a fatal metabolic disorder in babies, one for Duchenne muscular dystrophy that affects young boys, and a therapy for a rare neurodegenerative disease. These new medicines are still being tested, but their inclusion in ILAP offers real hope for conditions where few or no treatments have existed before.
ILAP stands out for involving the health service at every stage, so everyone like regulators, doctors, and patient representatives can agree early on what’s needed for a new drug to be safely and effectively delivered to the people who need it. With clearer guidance and a single point of contact for each medicine, companies know exactly what is expected, and decisions from different agencies can happen in parallel, not just one after another.
Rare diseases affect about 3 million people in the UK, yet most lack effective treatments. Developing new medicines is challenging due to small patient numbers and high trial costs.
The Innovative Licensing and Access Pathway (ILAP) helps speed up development by providing targeted support. From 16 applications, three treatments for rare diseases received an Innovation Passport, including therapies for:
- Neonatal onset OTC deficiency
- Duchenne muscular dystrophy
- A rare childhood neurodegenerative disease
This effort supports the UK’s 10-Year Health Plan and Life Sciences Sector Plan to improve diagnosis, treatment, and care for rare conditions. These therapies are still in development and will depend on proven safety and effectiveness.
Submit RFI/RFP